Vytorin First-Line Use Gains Traction, Schering Says
Sales of Schering-Plough/Merck’s cholesterol-lowering therapies Zetia and Vytorin each exceeded $1 bil. in sales in 2005.
Sales of Schering-Plough/Merck’s cholesterol-lowering therapies Zetia and Vytorin each exceeded $1 bil. in sales in 2005.